Enterprise Value
31.92M
Cash
198.1M
Avg Qtr Burn
-21.5M
Short % of Float
0.25%
Insider Ownership
5.84%
Institutional Own.
77.36%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
FPI-2265 Details Prostate cancer | Phase 2 Data readout | |
FPI-2059 Details Solid tumor/s | Phase 1 Data readout | |
FPI-1434 (targeted alpha radioimmunoconjugate) Details Solid tumor/s | Phase 1 Data readout | |
FPI-1966 Details Solid tumor/s, Head and neck cancer, Bladder cancer | Failed Discontinued |